This move is archived. Current quotes and coverage live on the stock page.
Get LABS alerts:

Medipharm Labs Corp's stock surged by 7.14% in the last trading session, signaling strong investor interest amidst improving financial metrics.
In a notable move on the TSX, Medipharm Labs Corp (LABS.TO) saw its stock price jump by 7.14% to close at CA$0.07. This increase reflects growing optimism among investors, particularly in light of the company's recent financial performance and strategic initiatives.
Investor takeaway: Investors are responding positively to Medipharm Labs' latest financial results and operational improvements, which may signal a turning point for the company.
Advertisement
Medipharm Labs Corp
LABS.TO
LABS.TO
Medipharm Labs Corp
Market cap
$32.04M
52W high
$0.10
52W low
$0.06
1W change
+0.00%
Beta
0.93
Analyst Price Targets
Based on analyst covering LABS
Wall Street analysts forecast LABS stock price to rise 33.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.10
+33.3% Upside
Current Price
C$0.07
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on LABS's historical volatility
30-Day Vol
54.8%
Annualized
90-Day Vol
73.8%
Annualized
Trend (90d)
+29.0%
Annualized drift
90d Mean
C$0.08
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$0.08 | C$0.06 โ C$0.09 |
| 60 trading days | C$0.08 | C$0.06 โ C$0.10 |
| 90 trading days | C$0.08 | C$0.06 โ C$0.12 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Medipharm Labs Corp's market cap reaches CA$31.86 million.
With a market cap of CA$31.86 million, Medipharm Labs is positioned as a small-cap player in the cannabis industry, which often comes with higher risk but also potential for significant returns.
Bull case
The recent surge in Medipharm Labs' stock is due to its reported positive adjusted EBITDA for Q1 2026 and a significant reduction in operating expenses. This could indicate a more sustainable business model moving forward.
Bear case
Despite the positive movement, the company still faces challenges. It has a negative profit margin and the inherent volatility of the cannabis sector, which could impact its future performance.
Recent Financial Performance
Advertisement
Medipharm Labs recently reported positive adjusted EBITDA for Q1 2026, with net revenue of $9 million and strong gross margins of 37%. This marks a significant improvement and has likely contributed to the stock's upward momentum.
Strategic Moves and Market Position
The company completed the sale of its Hope, BC facility for $4.5 million, allowing it to focus on expanding its EU GMP-certified cultivation capacity. This strategic shift positions Medipharm Labs to capitalize on growing international demand.
Investor Sentiment and Future Outlook
Investor sentiment appears to be shifting positively as Medipharm Labs demonstrates operational efficiencies and a commitment to improving its financial health. However, potential investors should remain cautious due to the volatile nature of the cannabis market.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement

Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.


